Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06930625 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
A Phase 3 study of Acromegaly, sponsored by Debiopharm International.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
- 20
- Study locations
NCT06930625: Recruiting Phase 3 study of Acromegaly, sponsored by Debiopharm International.
NCT06930625 is a Phase 3 study of Acromegaly that is actively recruiting participants, run by Debiopharm International. The registered enrollment target is 119 participants, above the 92-participant average among 13 other Acromegaly trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06930625, a Phase 3 study of Acromegaly, is actively recruiting participants, sponsored by Debiopharm International.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Debio 4126
Study Locations (20)
Other
- Medical University Graz - Graz
- Medizinische Universitaet Wien - Division of Endocrinology and Metabolism - Vienna
- UZ Gent - Ghent
- CETI - Centro de Estudos em Terapias Inovadoras - Curitiba
- Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM) - Fortaleza
- Instituto Estadual do Cérebro Paulo Niemeyer (IECPN) - Rio de Janeiro
- Hospital das Clinicas - University of Sao Paulo Medical School - São Paulo
- University Specialized Hospital for Active Treatment of Endocrinology Akad. lv Penchev EAD - Sofia
- Rigshospitalet, Blegdamsvej 9 - Copenhagen
- Zealand University Hospital - Køge
- East Tallinn Central Hospital - Tallinn
Ohio
- The Cleveland Clinic - Cleveland
- The Ohio State University - Columbus
California
- Cedars Sinai Medical Center - Los Angeles
Illinois
- Northwestern University - Chicago
Massachusetts
- Harvard Medical School - Boston
Missouri
- Washington University-School of Medicine - St Louis
Nevada
- Palm Research Center Inc - Las Vegas
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2025-11-26 |
| Est. Completion | 2029-03 |
| Phase | Phase 3 |
What NCT06930625 shows while recruiting
NCT06930625 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, above the 92-participant average among 13 other Acromegaly trials with a reported enrollment target (29% higher).
The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06930625 names 20 study sites across 9 states, led by Other, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT06930625 about?
NCT06930625 is a clinical study titled "A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs". The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.
What is the current status of trial NCT06930625?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2025-11-26. Estimated completion is 2029-03.
What conditions does trial NCT06930625 study?
This clinical trial studies the following conditions: Acromegaly.
What interventions are being tested in trial NCT06930625?
The interventions under investigation include: Placebo (DRUG), Debio 4126 (DRUG).
Who is sponsoring clinical trial NCT06930625?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06930625 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acromegaly
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06930625's enrollment target sits among peer trials
119 2nd of 13 the highest of 13 other Acromegaly trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acromegaly trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
ACTIVE NOT RECRUITING · Phase 3
-
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
COMPLETED · Phase 3
-
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
RECRUITING · Phase 2
-
Diet in the Management of Acromegaly
RECRUITING · NA
-
Study of MAR002 in Healthy Men
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI